Chancery Suit Targets Fee-Shifting Bylaw Enacted Before Ban
By Matt Chiappardi ( April 27, 2016, 10:54 PM EDT) -- A shareholder in StemCells Inc. launched a putative class action Wednesday in Delaware Chancery Court challenging the biopharmaceutical company's fee-shifting bylaw enacted the day the state Senate voted to ban the practice, and a later-added rule that effectively prohibits stockholders from recovering legal costs in a lawsuit....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.